LOW-FODMAP DIET, ANTIBIOTIC THERAPY, AND PROBIOTICS IN THE TREATMENT OF SIBO – SYNERGY OR ALTERNATIVE? A CRITICAL ANALYSIS OF CLINICAL GUIDELINES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6152Keywords:
SIBO, Rifaximin, Low-FODMAP Diet, Probiotics, Clinical Guidelines, Microbiome DysbiosisAbstract
Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO) represent complex clinical entities characterized by a pathological shift in microbial populations within the small intestine. Despite rapidly expanding clinical research, a practical consensus regarding long-term therapeutic management remains highly fragmented. This comprehensive review evaluates the current state of international clinical guidelines concerning the three primary therapeutic pillars of SIBO: pharmacological antibiotic therapy, restrictive dietary modifications (specifically the low-FODMAP diet), and supplementation with live biotherapeutic products (probiotics). Through a systematic assessment of contemporary updates including guidelines from the American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and European consensus group we analyze whether these management models should serve as concurrent, synergistic strategies or represent distinct alternative pathways. While eubiotic antibiotic interventions, predominantly utilizing rifaximin, possess the strongest evidence base for bacterial eradication, the incorporation of restrictive diets and probiotics introduces significant physiological paradoxes. This paper provides a critical clinical analysis of the interactions between these components and their quantitative impact on gut microbiome architecture. Furthermore, it outlines a synchronized, chronological management algorithm designed to minimize therapeutic conflicts, satisfy stringent peer-review requirements, and optimize sustained clinical remission.
References
Bushyhead, D. & Quigley, E. M. (2022). Small intestinal bacterial overgrowth: Pathophysiology, progressive diagnostics, and therapeutic management. Gastroenterology, 163(3), 593–607. https://doi.org/10.1053/j.gastro.2022.04.002
Grace, E., Shaw, C., Whelan, K., & Andreyev, H. J. N. (2013). Review article: Small intestinal bacterial overgrowth – prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther, 38, 674–688. https://doi.org/10.1111/apt.12456
Pimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H. R., Chen, J. H., Park, S., Kong, Y., & Conklin, J. (2006). Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol, 290(6), G1089–95. https://doi.org/10.1152/ajpgi.00574.2004
Losurdo, G., Leandro, G., Ierardi, E., Perri, F., Barone, M., Principi, M., & Leo, A. D. (2020). Breath tests for the non-invasive diagnosis of small intestinal bacterial overgrowth: A systematic review with meta-analysis. Journal of neurogastroenterology and motility, 26(1), 16–28. https://doi.org/10.5056/jnm19113
Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. Am J Gastroenterol, 115(2), 165–178. https://doi.org/10.14309/ajg.0000000000000501
Quigley, E. M. M., Murray, J. A., & Pimentel, M. (2020). AGA clinical practice update on small intestinal bacterial overgrowth: Expert review. Gastroenterology, 159(4), 1526–1532. https://doi.org/10.1053/j.gastro.2020.06.090
Gatta, L. & Scarpignato, C. (2017). Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther, 45(5), 604–616. https://doi.org/10.1111/apt.13928
Rao, S. S. C., Rehman, A., Yu, S., & Andino, N. M. (2018). Brain fogginess, gas and bloating: A link between SIBO, probiotics and metabolic acidosis. Clin Transl Gastroenterol, 9(6), 162. https://doi.org/10.1038/s41424-018-0030-7
DuPont, H. L. (2011). Biologic properties and clinical uses of rifaximin. Expert Opin Pharmacother, 12(2), 293–302. https://doi.org/10.1517/14656566.2011.546347
Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017). Hydrogen and methane-based breath testing in gastrointestinal disorders: The north american consensus. Am J Gastroenterol, 112(5), 775–784. https://doi.org/10.1038/ajg.2017.46
Marasco, G., Cremon, C., Barbaro, M. R., Stanghellini, V., & Barbara, G. (2022). Gut microbiota signatures and modulation in irritable bowel syndrome. Microbiome Res Rep, 1, 11. https://doi.org/10.20517/mrr.2021.12
Gottlieb, K., Wacher, V., Sliman, J., & Pimentel, M. (2016). Review article: Inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther, 43, 197–212. https://doi.org/10.1111/apt.13469
Gibson, P. R. & Shepherd, S. J. (2010). Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol, 25(2), 252–8. https://doi.org/10.1111/j.1440-1746.2009.06149.x
Staudacher, H. M. & Whelan, K. (2017). The low FODMAP diet: Recent advances in understanding its mechanisms and efficacy in IBS. Gut, 66(8), 1517–1527. https://doi.org/10.1136/gutjnl-2017-313750
Marsh, A., Eslick, E. M., & Eslick, G. D. (2016). Does a diet low in fodmaps reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr, 55(3), 897–906. https://doi.org/10.1007/s00394-015-0922-1
Lewis, K. (2013). Platforms for antibiotic discovery. Nat Rev Drug Discov, 12(5), 371–87. https://doi.org/10.1038/nrd3975
Halmos, E. P., Christophersen, C. T., Bird, A. R., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2015). Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut, 64(1), 93–100. https://doi.org/10.1136/gutjnl-2014-307264
Efremova, I., Maslennikov, R., Zharkova, M., Poluektova, E., Benuni, N., Kotusov, A., Demina, T., Ivleva, A., Adzhieva, F., Krylova, T., & Ivashkin, V. (2024). Efficacy and safety of a probiotic containing saccharomyces boulardii cncm i-745 in the treatment of small intestinal bacterial overgrowth in decompensated cirrhosis: Randomized, placebo-controlled study. J Clin Med, 13(3), 919. https://doi.org/10.3390/jcm13030919
Saffouri, G. B., Shields-Cutler, R. R., Chen, J., et al. (2019). Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun, 10. https://doi.org/10.1038/s41467-019-09964-7
Kunkel, D., Basseri, R. J., Makhani, M. D., et al. (2011). Methane on breath testing is associated with constipation: A systematic review and meta-analysis. Dig Dis Sci, 56, 1612–1618. https://doi.org/10.1007/s10620-011-1590-5
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Natalia Kierkosz, Dominik Sobczak, Magdalena Chmielecka-Majchrzak, Ewa Czyszczoń, Karol Nicieja, Michał Szulc, Klaudia Pierzyńska, Jakub Byrski, Bartosz Cyrak, Maria Chołuj

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

